Tag: business

Kao’s Laurier Launches New Brand Communication Initiative across Asia: Strengthening Global Integration as a Core Brand in Kao’s Asian Business

by jezzabellemente, posted in Uncategorized

Laurier Campaign Key Visual

TOKYO, March 4 (Bernama-BUSINESS WIRE) — Starting on International Women’s Day, March 8, Kao Corporation (TOKYO:4452) will launch new brand communication campaign in nine Asian countries and regions for its feminine sanitary product brand, Laurier, which is the core of its Asian business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303996141/en/

Laurier aims to help create more supportive and understanding environments around menstruation, so that women can feel more at ease, both physically and emotionally, under the key message “Comfort, Made Together,” which will be implemented simultaneously across Asia. Kao aims to further develop Laurier as a global brand.

Laurier, one of the core brands supporting Kao’s consumer care business in Asia, has been promoting globally integrated operations since 2023. Across all nine Asian countries and regions including Japan, Laurier has been working to unify product specifications and consolidate production sites to improve asset turnover ratio. Moreover, Laurier has promoted discussions to unify interpretations of the brand purpose and worldview, which varied across regions, and has renewed the global guidelines.

Through these efforts, in order to simultaneously communicate its value throughout Asia, Laurier is currently initiating a new brand communication initiative. By returning to Kao’s founding principle of a consumer perspective, Laurier will further strengthen brand equity by offering products designed for long-term use and advancing empathy-driven marketing through consistent communication across regions.

Laurier conducted a survey on attitudes toward menstruation among 4,500 women across nine Asian countries and regions.* The findings revealed that across Asia, many women feel that menstrual symptoms, concerns, and the limitations associated with menstruation have an impact on their overall sense of comfort in daily life.
*An online survey on attitudes toward menstruation was conducted by Kao among women aged 15–44 in nine Asian countries and regions, including Japan, in November–December 2023 and October–November 2024 (valid responses: 4,500).

Through this initiative, Laurier will further its efforts toward creating an inclusive environment where women can live lives full of possibilities without feeling restricted by their periods.
As a global brand, Laurier not only provides products but also supports women throughout their lives by providing information and educational support, contributing to the creation of a society where each woman can continue to live in a way that feels true to herself.

About the Brand Communication Initiative

– Key Message
Comfort, Made Together ―Laurier is here to listen.
It’s natural to find it difficult to be your normal self while you’re on your period. A woman shouldn’t have to find menstrual comfort on her own. We may not be able to completely eliminate physical discomfort or pain. But by encouraging understanding from those around us and shaping more supportive environments, we believe periods can feel a little more comfortable.
– Overview
This campaign will unify the brand’s worldview across nine Asian countries and regions, and will implement the following initiatives:

  • Development of a common key visual and message across Asia
  • Release of anthem films (9 country/regional versions) conveying Laurier’s message of menstrual support
  • Launch of a special campaign website

– Countries/Regions: Kao Corporation / Kao Commercial (Shanghai) Co., Ltd. / Kao (Hong Kong) Ltd. / Kao (Taiwan) Corporation / Kao Vietnam Co., Ltd. / Kao Industrial (Thailand) Co., Ltd. / Kao (Malaysia) Sdn. Bhd. / Kao Singapore Pte. Ltd. / PT Kao Indonesia
– Start Date: March 4, 2026

Ongoing Social Initiatives

As a brand that supports women, Laurier is continuously engaged in the following activities in each country and region.

  • Japan: “Laurier in Workplace” and “Laurier in School,” making sanitary napkins available as standard supplies at workplaces and schools
  • Indonesia: “Dr. Laurier,” providing expert knowledge on menstrual concerns that are hard to discuss with others

In addition to the above, Laurier provides menarche education to deliver accurate knowledge to individual in all nine countries and regions. Through these activities, Laurier will continue to be more than just a feminine sanitary product brand; it will continue to be a presence that supports women at all stages of their lives and in their social environments.

Comment from Kazuya Miyashita, President of the Sanitary Business, Kao Corporation

Laurier has been striving to strengthen its globally integrated operations. The launch of this new brand communication across nine Asian countries and regions marks the next stage in building a consistent global brand―one that transcends borders, listens to the voices of individual, and shares Laurier’s vision and values across Asia. While menstrual concerns and feelings vary from person to person, there are many aspects of menstruation that have been discussed as something to be endured or a personal issue. Through this communication campaign, Laurier aims to elevate menstrual concerns beyond a personal issue, encourage understanding from others, and foster an environment in which women can live with greater peace of mind. As a core brand in Kao’s Asian business, Laurier will continue to contribute to sustainable growth and the realization of a society where women can live their lives with comfort, confidence, and fewer limitations—no matter the day.

About Kao

Kao, a Japan-based manufacturer of personal care and household products, cosmetics, and specialty chemicals creates high-value-added products and services that provide care and enrichment for the life of all people and the planet. Through its brands such as Attack laundry detergent, Bioré and Jergens skin care products, Laurier sanitary products, Curél, SENSAI, and MOLTON BROWN cosmetics, and Oribe hair care products, Kao is part of the everyday lives of people across Asia, the Americas, Europe, the Middle East, and Africa. Combined with its chemical business, which contributes to a wide range of industries, Kao generates about 1,630 billion yen in annual sales. Kao employs about 32,600 people worldwide and has more than 130 years of history in innovation. As an enterprise that provides products people use on a daily basis, the Kao Group takes responsibility to actively reduce the environmental footprint of its products throughout the product lifecycle. This is laid out in Kao’s ESG strategy, the Kirei Lifestyle Plan, which launched in 2019.
Please visit the Kao Group website for additional information.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20260303996141/en/

Contact

Media inquiries should be directed to:
Public Relations
Kao Corporation
corporate_pr@kao.com

Source : Kao Corporation

Green Building Initiative Launches Ascent Building Certification™ for Global Markets

by jezzabellemente, posted in Uncategorized

New portfolio-ready building certification delivers proven tools to achieve credible sustainability and performance outcomes worldwide

PORTLAND, Ore., March 4 (Bernama-GLOBE NEWSWIRE) — The Green Building Initiative (GBI) announces the global launch of Ascent Building Certification™, a science-based whole building certification designed to evaluate sustainability, health, and resilience practices for all types of commercial real estate across regions and portfolios. Ascent will be used for new and existing projects in the EU, the UK, and elsewhere outside Canada and the United States to improve the built environment’s impact on climate and society.

Ascent Building Certification™ is a global expansion of GBI’s trusted third-party assessment and certification programs. GBI has certified over 93 million square meters (1 billion square feet) of commercial real estate, leading with its flagship certification, Green Globes®. Strong adoption of Green Globes combined with market demand for a robust, proven, and transparent certification that delivers consistent methodology across borders and portfolios led GBI to expand its flagship certification globally under the Ascent™ brand.

Designed for owners and project teams managing assets in all lifecycle phases, Ascent provides a consensus-based framework, consistent with Green Globes, that adapts to local standards and regulatory requirements. The certification responds to growing market demand for certification systems that combine transparency, a trustworthy independent assessment, and practical usability—without unnecessary administrative burden.

“Building owners and investors are facing increasing pressure to demonstrate measurable performance and return on investment across global portfolios,” said Vicki Worden, CEO of GBI. “GBI’s Ascent Building Certification answers that demand with a practical, transparent, and ESG-aligned approach.”

Ascent is designed to serve organizations seeking user-friendly, portfolio-ready certification. Key features include:

  • Global consistency with local relevance through a unified framework adaptable to regional regulations and environmental conditions
  • Transparent scoring and results that support credible reporting and stakeholder confidence
  • Independent third-party assessment conducted through GBI’s established assessor network
  • User-friendly software tools with centralized reporting dashboards and aggregated portfolio scoring
  • Dedicated expert support from GBI’s team of green building specialists and project managers
     

Certification levels align with the Green Globes One through Four rating system, and performance categories address critical building outcomes and Environmental Assessment Areas, including project management and responsible business practices, site, energy, water, materials, and indoor environment.

By combining transparent scoring, independent certification, structured expert guidance, and user-friendly tools, Ascent reduces friction in the certification process while maintaining rigorous performance standards.

Organizations can learn more or begin the certification process at:
https://thegbi.org/assessment-certification/ascent-certification/

For media inquiries, contact megan@thegbi.org.

About GBI

GBI is an international nonprofit organization and American National Standards Institute (ANSI) Accredited Standards Developer dedicated to improving the built environment’s impact on climate and society. Founded in 2004, the organization is the global provider of the Green Globes®, Journey to Net Zero™, Guiding Principles Compliance, and Ascent Building Certification™ and assessment programs. GBI also issues professional credentials, including the Green Globes Professional (GGP) and Guiding Principles Compliance Professional (GPCP). To learn more about opportunities to become involved with GBI, contact info@thegbi.org or visit the GBI website at www.thegbi.org.

MEDIA CONTACT
Megan Baker, GBI Vice President of Engagement, megan@thegbi.org, (971) 256-7174

SOURCE: Green Building Initiative

STB’s Virtual Assistant Alma Redefines How Travelers Explore Slovenia

by jezzabellemente, posted in Uncategorized

LJUBLJANA, Slovenia, Dec 17 (Bernama-GLOBE NEWSWIRE) —TheSlovenian Tourist Board (STB) is strengthening Slovenia’s position as a digitally advanced, user-focused destination with Alma, an AI-powered virtual travel advisor that has rapidly become one of the country’s most innovative tourism tools. Integrated into the national tourism portal slovenia.info, Alma enables visitors to access personalised and up-to-date travel information in real time, marking a major step in the STB’sdigital transformation efforts.

Launched in May 2024, Alma engages users in conversational, intuitive exchanges across seven languages, providing tailored guidance, inspiring stories and practical tips for exploring Slovenia. Named after traveller and writer Alma M. Karlin, the assistant is built on advanced OpenAI technology and sources information from the slovenia.info database and more than 60 curated tourism websites and API integrations.

Since its introduction, Alma has gained significant recognition. It earned silver in the Tourism category at the 2024 Websi Awards, praised for its intelligent integration with the website’s search engine and for enhancing user interaction on a national tourism platform. More recently, Alma won the prestigious Travel Tech Project of the Year at the 2025 Game Changer Awards, underscoring Slovenia’s leadership in developing responsibly designed, user-friendly digital solutions for the future of travel.

MSc. Maja Pak Olaj, the Director of the Slovenian Tourist Board, emphasised: “Alma represents an important step towards modern, intelligent and personalised services that make exploration of Slovenia easier. The award recognises our efforts toward innovation and confirms that thoughtful use of technology can create greater value for tourists, partners, and the entire Slovenian tourism sector.”

Alma’s impact is reflected in its strong adoption figures. In August 2025 alone, users asked nearly 12,000 questions, with English, Italian, German and Slovenian speakers representing the largest share. The assistant achieved an 88% positive rating that month, rising to 91% in October and November, reflecting high satisfaction.

Travellers increasingly rely on Alma to plan multi-day itineraries, discover lesser-known regions, choose family-friendly activities, explore culinary and cultural events and access sustainable mobility options. Continuous upgrades – including a redesigned mobile interface, dynamic suggestions and multilingual adaptation – further strengthen its role as a digital companion. Looking ahead, the STB is developing “Admin Alma” to allow destinations to enrich the assistant with local insights, and plans to evolve Alma into a real-time voice guide supporting visitors throughout their journey.

More information: 
https://www.slovenia.info/en/business/content-digital-marketing/alma-slovenian-ai-travel-guide

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/614ec2a1-ff5d-4362-8310-12fcdb6c12ae

press@slovenia.info

SOURCE: Slovenian Tourist Board

–BERNAMA

Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, and Drug Information

by jezzabellemente, posted in Uncategorized

PHILADELPHIA, Nov 5 (Bernama-GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today announced that it has granted a worldwide exclusive license, with the right to sublicense, to Scilex Holding Company (Nasdaq: SCLX), for Datavault AI’s proprietary AI-driven technology. This license is tailored for use within the biotech and biopharma industry, enabling Scilex to create and operate a Biotech Exchange platform. By leveraging Datavault AI’s advanced data platforms, Scilex can facilitate secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostic and therapeutic products, genetic information, and drug data. This agreement represents a major advancement in commercializing biotech innovations and builds directly on Datavault AI’s established expertise in high-performance computing and data-driven solutions.

Datavault AI believes this technology has the potential to extend into a Pharmaceutical Exchange platform, which could transform the pharmaceutical industry by enabling efficient, secure asset management and monetization.

Datavault AI estimates an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales.1 The Company also sees tokenization on such exchange platforms as an alternative for companies to secure non-dilutive funding for developing and commercializing diagnostic and therapeutic products.

This licensing agreement highlights Datavault AI’s robust intellectual property portfolio, including the key pending patent for “Platform and Method for Tokenizing DNA Data” (U.S. Patent Application No. 17/941,623), which establishes a secure framework for tokenizing and exchanging sensitive genetic information. The technology is bolstered by a comprehensive suite of issued and pending patents that power the Biotech Exchange, such as:

  • Issued: “Platform for Management of User Data” (U.S. Patent Nos. 11,593,515; 11,960,622; 12,100,025) and continuations, supporting secure data handling and monetization.
  • Issued: “Portfolio Driven Targeted Advertising Network, System, and Method” (U.S. Patent No. 11,315,150), facilitating data-driven targeting within exchange ecosystems.
  • Pending: “System and Method for Tokenized Minting, Authentication, and Utilization of Assets” (U.S. Patent Application No. 17/842,139), enabling biotech asset tokenization.
  • Pending: “Platform and Method for Tokenization of Corporate Data” (U.S. Patent Application No. 17/941,550), adaptable to biotech datasets.
  • Pending: “System and Method for Tokenized Licensing of Content” (U.S. Patent Application No. 17/842,328), for biotech IP licensing.
  • Pending: “System and Method for Tokenized Affiliate Marketing” (U.S. Patent Application No. 17/842,265), to foster biotech partnerships.
  • Pending: “System and Method for Funding a Virtual Location” (U.S. Patent Application No. 17/842,220), applicable to virtual biotech marketplaces.
  • Pending: “System and Method for Tokenized Event Management” (U.S. Patent Application No. 19/248,284), for biotech events and collaborations.
  • Pending: “System and Method for Registering Claims of Ownership Rights” (U.S. Patent Application No. 18/412,128), ensuring verifiable ownership in data trades.

These innovations collectively form the backbone of a secure, efficient Biotech Exchange, enabling tokenization, valuation, and trading of biotech data assets while upholding compliance and privacy.

Building on Datavault AI’s prior collaborations with Brookhaven National Laboratory, as announced in our June 17, 2025, press release, where we deployed AI-driven supercomputing for biofuel research to enhance fatty acid metabolism efficiency in Brassica napus (canola) using high-performance computational modeling, this license extends our proven AI and data monetization technologies into broader biotech applications. This follows our Sept. 16, 2024, announcement highlighting the Bioenergy Digital Twins Platform at the New York State Digital Summit, emphasizing real-time data synchronization and machine learning integration for bioenergy advancements.

Under the terms of the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and Sept. 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

Terms of License

Under the terms of the agreement, Datavault AI will receive a non-refundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

For more information on Datavault AI, visit www.dvlt.ai.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science Division leverages high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI’s cloud-based platform serves multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, Pennsylvania.

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), which is owned by Semnur (a majority-owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California. For more information, visit www.scilexholding.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, the Company’s license agreement with Scilex, the potential opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales, Datavault AI’s ability to support Scilex in leveraging its platforms for secure tokenization, trading, and monetization of biotech assets, the potential creation of a Pharmaceutical Exchange platform, expectations as to the opportunity to tokenize pharmaceutical drug sales and diagnostic sales, including the size of such opportunity, future opportunities for Datavault AI, its business strategies, long-term objectives, and commercialization plans, the current and prospective technologies, planned developments and potential approvals, as well as the potential for market acceptance and related market opportunities, and other statements that are not historical facts. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Datavault AI. These statements are subject to a number of risks and uncertainties regarding Datavault AI’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political, and business conditions; the ability of Datavault AI to achieve the benefits of the license agreement and other transactions contemplated with Scilex, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Scilex, including the license agreement; the risk that the transactions contemplated with Scilex disrupt current plans and operations; the ability of Datavault AI to develop and successfully market technologies; the ability of Datavault AI to grow and manage growth profitably and retain its key employees; the risk that the potential technologies that Datavault AI develops may not progress or receive required approvals within expected timelines or at all; risks relating to uncertainty regarding regulatory pathways; the risk that Datavault AI has overestimated the size of the target market, willingness to adopt new technologies, or partnerships; risks that prior results may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Scilex; the risk that Datavault AI will not benefit from a Pharmaceutical Exchange platform; and other risks and uncertainties indicated from time to time in Datavault AI’s filings with the SEC. There may be additional risks that Datavault AI presently does not know or that Datavault AI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Datavault AI’s expectations, plans, or forecasts of future events and views as of the date of this communication. Datavault AI anticipates that subsequent events and developments will cause such assessments to change. However, while Datavault AI may elect to update these forward-looking statements at some point in the future, Datavault AI specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Datavault AI’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. 

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Media Inquiries:
marketing@dvlt.ai
Website: www.dvlt.ai

1References
Sources for Pharmaceutical Drug Sales Data

The data for global pharmaceutical drug sales was primarily drawn from IQVIA Institute reports on global medicine spending, excluding COVID-19 vaccines and therapeutics for consistency. Here is the list of key sources referenced:

Sources for Diagnostic Sales Data

The data for global in vitro diagnostics (IVD) market sales was compiled from market research reports, with forecasts based on observed CAGRs (around 6.9% from 2020-2024). IQVIA provides qualitative insights, but quantitative figures were cross-referenced from other industry analyses for accuracy. Here is the list of key sources referenced:

SOURCE: Datavault AI Inc. 

DISCLAIMER: BERNAMA MREM are not accountable for any causes of website defacement, misuse, or illegal activities connected to cryptocurrency, blockchain, tokenisation, or bitcoin. This material should not be considered as guidance or an opinion, as it does not constitute financial or investment advice. Use this information at your own risk; we are not liable for any losses or damages caused by the republication of this article.

Kao Releases the Kao Integrated Report 2025

by jezzabellemente, posted in Uncategorized

The cover visual represents our “moonshot.” It embodies our commitment to achieving the ambitious goal of a sustainable society for future generations.

TOKYO, June 13 (Bernama-BUSINESS WIRE) — Kao Corporation (TOKYO:4452) has published the Kao Integrated Report 2025 on its website, offering shareholders, investors, and all stakeholders with a comprehensive overview of the company’s initiatives and strategic direction.
Kao Integrated Report 2025

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609991718/en/

To achieve its Mid-term Plan “K27,” Kao aims to become a unique presence indispensable to someone in the world and is advancing its Global Sharp Top strategy. In FY2024, Kao exceeded its targets by strengthening Return on Invested Capital (ROIC) management and strategically investing to build stronger, more robust businesses.

This report offers an in-depth look at Kao’s progress under K27, highlighting how Kao’s dedicated employees—through the Global Sharp Top strategy and agile scrum team approach—are actively creating new value and driving meaningful impact. It also outlines Kao’s ongoing efforts to take on bold challenges by leveraging its unique scientific expertise to address global social issues and help realize a Kirei world where all life lives in harmony.

Kao hopes this report deepens stakeholders’ understanding and fosters meaningful dialogue and collaboration. The company is committed to actively incorporating feedback and insights from diverse partners as it continues to enhance its positive contributions to society and corporate value.

Related Information
Kao Sustainability Report 2025

About the Kirei Lifestyle Plan
Over the past 130 years, Kao has worked to improve people’s lives and help them realize more sustainable lifestyles—a Kirei Lifestyle. The Japanese word “kirei” describes something that is clean, well-ordered, and beautiful all at once. For Kao, this concept of “kirei” not only describes appearance but also attitude—a desire to create beauty for oneself, for other people, and for the natural world around us. Aiming to realize a more sustainable way of living, in April 2019, the Kao Group established its ESG strategy known as the Kirei Lifestyle Plan. By 2030, Kao aims to empower at least 1 billion people, to enjoy more beautiful lives. Kao also strives to have 100% of its products leave a full lifecycle environmental footprint that science says our natural world can safely absorb.
Please visit the Kao sustainability website for more information.

About Kao
Kao, a Japan-based manufacturer of personal care and household products, cosmetics, and specialty chemicals creates high-value-added products and services that provide care and enrichment for the life of all people and the planet. Through its brands such as Attack laundry detergent, Bioré and Jergens skin care products, Laurier sanitary products, Curél, SENSAI, and MOLTON BROWN cosmetics, and Oribe hair care products, Kao is part of the everyday lives of people across Asia, the Americas, Europe, the Middle East, and Africa. Combined with its chemical business, which contributes to a wide range of industries, Kao generates about 1,630 billion yen in annual sales. Kao employs about 32,600 people worldwide and has more than 130 years of history in innovation. As an enterprise that provides products people use on a daily basis, the Kao Group takes responsibility to actively reduce the environmental footprint of its products throughout the product lifecycle. This is laid out in Kao’s ESG strategy, the Kirei Lifestyle Plan, which launched in 2019.
Please visit the Kao Group website for additional information.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20250609991718/en/

Contacts

Media inquiries should be directed to:
Public Relations
Kao Corporation
corporate_pr@kao.com

Source: Kao Corporation